一体化18F-FDG PET/MRI在乳腺癌中的应用:新辅助化疗早期疗效预测
该前瞻性研究纳入26例接受新辅助化疗(NAC)并手术的乳腺癌患者,在首周期NAC前后行18F-FDG PET/MRI检查。结果显示,pCR组TLG30%和SER的平均下降百分比均显著大于非pCR组,联合TLG30%与SER标准预测非pCR的敏感性为100%、特异性为71.4%。作者认为18F-FDG PET/MRI可预测首周期NAC后的非pCR,加入MRI参数有潜力提高敏感性。
要点
- 26例中7例(26.9%)达pCR,19例(73.1%)为非pCR。
- pCR组TLG30%平均下降64.8% vs 非pCR组25.4%,P=0.005。
- 联合TLG30%与SER预测非pCR:敏感性100%(19/19),特异性71.4%(5/7)。
核心结论
- 18F-FDG PET/MRI可预测乳腺癌患者首周期NAC后的非pCR,加入MRI参数有潜力提高敏感性。
研究设计与样本
- 前瞻性纳入2014年11月至2016年4月间接受NAC并后续手术的26例乳腺癌患者,每例在首周期NAC前后行18F-FDG PET/MRI检查。
主要发现
- 26例中7例(26.9%)为pCR,19例(73.1%)为非pCR。
- pCR组与非pCR组在定性MRI参数上无显著差异。
- pCR组TLG30%平均下降百分比为64.8±15.5%,非pCR组为25.4±48.7%,P=0.005。
- pCR组SER平均下降百分比为34.6±19.7%,非pCR组为8.7±29.0%,P=0.040。
- TLG30%变化百分比预测pCR的AUC为0.789(95%CI 0.614-0.965),SER变化百分比预测pCR的AUC为0.789(95%CI 0.552-1.000),两者比较P=1.000。
关键数值与推荐
- TLG30%预测pCR的特异性为100%(7/7),SER预测pCR的特异性为71.4%(5/7)。
- TLG30%预测非pCR的敏感性为63.2%(12/19),SER预测非pCR的敏感性为84.2%(16/19)。
- 联合TLG30%与SER标准预测非pCR的敏感性为100%(19/19),特异性为71.4%(5/7)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To explore whether integrated 18F-FDG PET/MRI can be used to predict pathological response to neoadjuvant chemotherapy (NAC) in patients with breast cancer. METHODS: Between November 2014 and April 2016, 26 patients with breast cancer who had received NAC and subsequent surgery were prospectively enrolled. Each patient underwent 18F-FDG PET/MRI examination before and after the first cycle of NAC. Qualitative MRI parameters, including morphological descriptors and the presence of peritumoral oedema were assessed. Quantitatively, PET parameters, including maximum standardized uptake value, metabolic tumour volume and total lesion glycolysis (TLG), and MRI parameters, including washout proportion and signal enhancement ratio (SER), were measured. The performance of the imaging parameters singly and in combination in predicting a pathological incomplete response (non-pCR) was assessed. RESULTS: Of the 26 patients, 7 (26.9%) exhibited a pathological complete response (pCR), and 19 (73.1%) exhibited a non-pCR. No significant differences were found between the pCR and non-pCR groups in the qualitative MRI parameters. The mean percentage reductions in TLG30% on PET and SER on MRI were significantly greater in the pCR group than in the non-pCR group (TLG30% -64.8 ± 15.5% vs. -25.4 ± 48.7%, P = 0.005; SER -34.6 ± 19.7% vs. -8.7 ± 29.0%, P = 0.040). The area under the receiver operating characteristic curve for the percentage change in TLG30% (0.789, 95% CI 0.614 to 0.965) was similar to that for the percentage change in SER (0.789, 95% CI 0.552 to 1.000; P = 1.000).The specificity of TLG30% in predicting pCR) was 100% (7/7) and that of SER was 71.4% (5/7). The sensitivity of TLG30% in predicting non-pCR was 63.2% (12/19) and that of SER was 84.2% (16/19). When the combined TLG30% and SER criterion was applied, sensitivity was 100% (19/19), and specificity was 71.4% (5/7). CONCLUSION: 18F-FDG PET/MRI can be used to predict non-pCR after the first cycle of NAC in patients with breast cancer and has the potential to improve sensitivity by the addition of MRI parameters to the PET parameters.
引用
- Cho N, Im SA, Cheon GJ, et al. Integrated 18F-FDG PET/MRI in breast cancer: early prediction of response to neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging. 2017. PMID: 29101445. doi:10.1007/s00259-017-3849-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。